The Life Sciences team represented HOOKIPA Pharma Inc. on the closing of its $84 million initial public offering of 6,000,000 shares of its common stock at a price to the public of $14.00 per share. HOOKIPA’s shares began trading on The Nasdaq Global Select Market on April 18 under the ticker symbol “HOOK.”
HOOKIPA is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, VaxWave, a replication-deficient viral vector, and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s lead infectious disease product candidate, HB-101, is currently in a Phase 2 clinical trial and their lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers.
The Goodwin team was led by partners Seo Salimi, Robert Puopolo and Kingsley Taft, and associates Michelle Wilensky, Will Magioncalda, Nicholas Reist and Thomas Schaad with assistance from partners Duncan Greenhalgh, Roger Cohen, Ettore Santucci and Rick Kline, counsel Stephanie Philbin, associates Olivia Uitto, Elizabeth Mulkey, Allyson Maur and paralegals Pamela Finan and Nathan Needle.
For additional details on the offering, please read the press release.